ADRB3

ADRB3 is a Gs-coupled β3-adrenergic receptor that transduces sympathetic catecholamine signals into cAMP-dependent responses across adipose, reproductive, vascular, and immune tissues, governing lipolysis, thermogenesis, smooth muscle relaxation, and endocrine communication. In brown adipocytes, ADRB3 activation drives cAMP-PKA-CREB signaling to induce UCP1-mediated thermogenesis via an S100B effector arm, suppresses exosomal iNOS release that otherwise promotes cardiac remodeling, and engages a KLF7-dependent transcriptional program for stress-induced IL-6 secretion (PMID:35652349, PMID:41343575, PMID:41565113, PMID:39515102). In white adipose tissue, sympathetic norepinephrine activates ADRB3 to stimulate hormone-sensitive lipase-dependent lipolysis, a pathway negatively regulated by the E3 ubiquitin ligase WWP1 and gated by suprachiasmatic nucleus circadian output (PMID:40362456, PMID:41343575). In human myometrium and placental vasculature, ADRB3 mediates cAMP-dependent smooth muscle relaxation, resists agonist-induced desensitization, and exerts anti-apoptotic and anti-inflammatory effects, with its protein expression reduced in preeclampsia (PMID:17570158, PMID:17989355, PMID:16177222).

1. 2005 High

   Demonstrating that ADRB3 is functionally active in human placental vasculature established it as a cAMP-coupled vasorelaxant receptor outside classical adipose contexts, and revealed that preeclampsia selectively reduces its protein without altering mRNA.

   Evidence Pharmacological relaxation of human placental artery rings with selective agonists, cAMP quantification, Western blot, and RT-PCR

   PMID:16177222

   Open questions at the time

   • Mechanism of post-transcriptional ADRB3 protein downregulation in preeclampsia not identified
   • Downstream effectors of cAMP-mediated vasorelaxation not delineated
2. 2007 High

   Showing that ADRB3 is the predominant β-adrenoceptor in human myometrium and mediates desensitization-resistant relaxation reframed it as a tocolytic target, while a parallel study demonstrated ADRB3 agonism prevents LPS-induced apoptosis and cytokine release, linking ADRB3 to anti-inflammatory and anti-apoptotic signaling in reproductive tissue.

   Evidence Human myometrial strip contraction assays, cAMP measurements, RT-PCR, pharmacological blockade; LPS-stimulated myometrial explants with Western blot, immunostaining, and caspase-3/BAX/BCL2 analysis

   PMID:17570158 PMID:17989355

   Open questions at the time

   • Intracellular pathway from cAMP to apoptosis suppression not fully dissected
   • Whether desensitization resistance is unique to myometrium or a general ADRB3 property remains untested
3. 2009 Medium

   Using Adrb3-knockout mice to show the receptor is required for the antidepressant-like behavioral effects of the selective agonist amibegron extended ADRB3 function into the central nervous system.

   Evidence Adrb3 KO mice in chronic mild stress paradigm with pharmacological challenge

   PMID:19744528

   Open questions at the time

   • Brain region and cell type expressing functional ADRB3 not identified
   • Downstream signaling mediating behavioral effect unknown
   • Single behavioral paradigm from one lab
4. 2013 High

   Reconstituting missense ADRB3 variants (Ser165Pro, Ser257Pro) in two cell lines showed that specific residues are required for cAMP signaling without affecting surface trafficking, providing a structure-function map of the receptor.

   Evidence Site-directed mutagenesis with stable expression in HEK293 and CHO-K1 cells, cAMP assay, confocal microscopy

   PMID:23640967

   Open questions at the time

   • No structural model explaining how these residues affect G-protein coupling
   • Physiological consequences of these variants in vivo not tested
5. 2014 High

   Identifying ADRB3 as the receptor through which norepinephrine inhibits MSC migration and osteogenic differentiation revealed a non-metabolic role for sympathetic-ADRB3 signaling in bone biology.

   Evidence siRNA knockdown of Adrb3 in MSCs plus in vivo sympathetic denervation in rat mandibular distraction model

   PMID:25144690

   Open questions at the time

   • Whether ADRB3 is the sole adrenergic receptor on MSCs mediating these effects is not excluded
   • Direct downstream signaling from ADRB3 in MSCs not mapped
6. 2021 Medium

   Validating miR-18a as a direct negative regulator of ADRB3 mRNA, itself suppressed by HDAC3, established an epigenetic–post-transcriptional axis (HDAC3→miR-18a→ADRB3) that upregulates ADRB3 in heart failure and promotes cardiac hypertrophy.

   Evidence Dual luciferase reporter assay confirming miR-18a–ADRB3 3′UTR interaction; gain/loss-of-function in HF mouse model with Western blot, TUNEL, flow cytometry

   PMID:33549119

   Open questions at the time

   • Whether ADRB3 upregulation is causative or correlative in heart failure progression not directly tested by rescue
   • Single-lab finding
7. 2022 High

   Brown adipocyte-specific ADRB3 knockout revealed that ADRB3 suppresses exosomal iNOS release; loss of this suppression drives cardiac fibroblast dysfunction, hypertrophy, and fibrosis, establishing a brown fat–heart endocrine axis mediated by exosomes.

   Evidence Conditional Adrb3 KO in brown adipocytes, Ang II cardiac stress model, exosome isolation and intravenous injection, iNOS knockdown rescue, cardiac functional assessment

   PMID:35652349

   Open questions at the time

   • Mechanism by which ADRB3 signaling controls iNOS loading into exosomes not resolved
   • Whether this axis operates in humans unknown
8. 2022 Medium

   Demonstrating that ADRB3 knockout in PyMT mice impairs mammary tumorigenesis and metastasis, and that ADRB3 promotes tumor cell proliferation via mTOR and MDSC expansion, extended receptor function into cancer immunobiology.

   Evidence ADRB3 KO PyMT mouse model, proliferation/differentiation assays, MDSC quantification by flow cytometry

   PMID:35145073

   Open questions at the time

   • Whether ADRB3 acts cell-autonomously in tumor cells versus through the immune microenvironment not fully separated
   • Mechanism linking ADRB3 to mTOR activation not delineated
9. 2024 Medium

   Pharmacological and genetic evidence placed ADRB3 upstream of UCP1-mediated thermogenesis in adipocytes, with swertiamarin identified as a direct ADRB3-binding agonist that drives glucose uptake, lipolysis (p-HSL), and mitochondrial biogenesis.

   Evidence HFD/STZ T2DM mouse model, 3T3-L1 adipocytes with ADRB3 inhibitor reversal, Western blot, metabolic measurements

   PMID:39515102

   Open questions at the time

   • Binding site and affinity of swertiamarin for ADRB3 not structurally characterized
   • Relative contribution of ADRB3 versus other adrenergic receptors in this model not fully excluded
10. 2025 Medium

    Integrating SCN lesioning with ADRB3 agonist studies identified S100B as both necessary and sufficient for ADRB3-driven brown adipocyte thermogenesis, embedding ADRB3 within a circadian clock–sympathetic–BAT circuit (SCN→sympathetic tone→ADRB3→cAMP→S100B).

    Evidence SCN lesioning, circadian arrhythmia models, in vivo ADRB3 agonist, S100B necessity/sufficiency experiments, indirect calorimetry

    PMID:41343575

    Open questions at the time

    • Transcriptional or post-translational mechanism linking cAMP to S100B upregulation not defined
    • Whether S100B acts cell-autonomously or through paracrine signaling not resolved
11. 2025 High

    Two concurrent studies clarified upstream regulators and downstream effectors of ADRB3 in adipose tissue: WWP1 was shown to suppress Adrb3 mRNA to limit lipolysis in WAT, while KLF7 was identified as a CREB-induced transcription factor required for ADRB3-stimulated IL-6 secretion from brown adipocytes during stress.

    Evidence Wwp1 KO mice on HFD with RT-qPCR and p-HSL Western blot; Klf7 adipocyte-specific KO mice with ADRB3 agonist, CREB ChIP on KLF7 promoter, PKA/CREB inhibitors, IL-6 ELISA

    PMID:40362456 PMID:41565113

    Open questions at the time

    • Mechanism by which WWP1 suppresses Adrb3 transcription (direct ubiquitination of a transcription factor?) unknown
    • Whether the KLF7–IL-6 axis operates in human brown fat not tested

• The structural basis for ADRB3's resistance to desensitization, the mechanisms controlling exosomal iNOS packaging, and the identity of WWP1's substrate that controls Adrb3 transcription remain unresolved.
• No high-resolution structure of human ADRB3 in active or inactive state
• Mechanism of desensitization resistance not molecularly defined
• Direct ubiquitination target of WWP1 upstream of Adrb3 unknown